According to a story from Markets Insider, the biopharmaceutical company CStone Pharmaceuticals has announced that China’s National Medical Products Administration (NMPA) has approved avapritinib (marketed
Machine Learning Could Improve FXS Diagnostic Process- April 13, 2021
PODCAST: WAIT, HOW DO YOU SPELL THAT?
LATEST PATIENT WORTHY ARTICLES
The month of April is recognized as Sarcoidosis Awareness Month, a time for spreading awareness about sarcoidosis among the general public and the medical community.
Recently, the Cancer Foundation of Santa Barbara (CFSB) was given a $500,000 grant courtesy of the Dr. Howard R. Bierman and Anthony Granatelli Fund. Altogether,
According to Yahoo Finance, immuno-oncology company Surface Oncology (“Surface”) recently received Orphan Drug designation for its leading therapeutic candidate SRF617. Altogether, this therapy is designed
Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we
Orphazyme’s latest trial has ended in failure after arimoclomol, a possible treatment of inclusion body myositis (IBM), failed to meet any of its endpoints. As
STUDY OF THE WEEK
April 14 @ 6:00 pm - 7:00 pm
The MDS Foundation’s Clinical Implications of Genetic Mutations in Myelodysplastic Syndromes WebinarApril 17 @ 12:00 pm - 1:00 pm
April 19 @ 6:00 pm - 7:30 pm
April 20 @ 5:00 pm - 6:00 pm